Therapy Evaluation News Today

Amsterdam's H-TEAM initiative has achieved a significant reduction in HIV infections from 2010 to 2022 using a city-centered approach. By combining treatments, including testing, pre-exposure prophylaxis, and stakeholder collaboration, the city has surpassed the UNAIDS 95-95-95 target and is on track to potentially eliminate HIV entirely in the near future.

Exelixis is a young commercial stage biopharma that is enjoying success with its CABOMETYX. Read more to see why I consider EXEL stock a near-term buy.

Some postmenopausal women with breast cancer do not benefit from chemotherapy when it’s added to hormone therapy, according to initial results of a clinical trial. The findings apply to postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to a limited number of lymph nodes, and whose recurrence risk is relatively low. The findings may save tens of thousands of postmenopausal women each year the time, m...